AXGN Earnings Date: Feb 23, 2027 (Estimated) — AxoGen, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is AXGN's next earnings date?
AxoGen, Inc. (AXGN) is expected to report Q4 2026 earnings on Tuesday, February 23, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.09 on revenue of $75.2M.
How did AXGN do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), AxoGen, Inc. posted EPS of $0.21 versus the $0.13 estimate, a beat of 59.9%. Revenue was $75.8M against a $73.2M estimate. The stock's 1-day post-earnings move was +31.5%.
How much does AXGN stock move after earnings?
AXGN beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.0% (up or down) in the day after earnings.
About AxoGen, Inc.
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
🤖 AI Earnings Analysis
Axogen delivered a strong Q3, with revenue rising 27% year over year to $76 million and EPS of $0.21 beating estimates by $0.08. Operating income was $2 million, though the reported -7% margin tempers the quality of growth.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | 0.13 | 0.21 | +59.94% | $75.8M | ✅ Beat | +31.47% | — | — |
| 2026-07-29 | Q2 2026 | 0.09 | 0.12 | +33.33% | $69.7M | ✅ Beat | +0.53% | +11.69% | +25.35% |
| 2026-04-28 | Q1 2026 | -0.07 | 0.07 | +200.00% | $61.5M | ✅ Beat | +6.60% | +8.23% | +1.22% |
| 2026-02-24 | Q4 2025 | 0.04 | 0.07 | +75.00% | $59.9M | ✅ Beat | -8.14% | -13.37% | -7.83% |
| 2025-10-29 | Q3 2025 | 0.03 | 0.12 | +300.00% | $60.1M | ✅ Beat | +23.06% | +31.47% | +57.91% |
| 2025-08-05 | Q2 2025 | 0.02 | 0.12 | +500.00% | $56.7M | ✅ Beat | +9.32% | +11.63% | +24.38% |
| 2025-02-25 | Q4 2024 | 0.04 | 0.07 | +75.00% | $49.4M | ✅ Beat | +11.66% | +7.11% | +5.44% |
| 2024-11-07 | Q3 2024 | 0.01 | 0.07 | +600.00% | $48.6M | ✅ Beat | -13.44% | -18.20% | -2.74% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q3 FY26 · $75.8M total
| Segment | Share | Revenue | YoY | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| UNITED STATES | 99.0% | $75.1M | — | $69.0M | $75.1M |
| Non-US | 1.0% | $780K | — | $726K | $780K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.